The Lancet Oncology in conversation with

Epizody

• 
  Accelerating equitable cancer genomics and precision oncology with Raffaella Casolino and Mark Lawler 25.09.2026 15min

  In this special episode, Dr Cheryl Lai, Acting Deputy Editor at The Lancet Oncology, is joined by Dr Raffaella Casolino (University of Glasgow, UK; International Cancer Genome Consortium - Accelerating Research in Genomic Oncology) and Professor Mark Lawler (Queen's University Belfast, UK) to discuss the outcomes and implications of the latest Lancet Oncology Commission on cccelerating equitable cancer genomics and precision oncology in health care and research. Explore the Commission and related content: https://www.thelancet.com/commissions-do/accelerating-equitable-cancer-genomics Look at the infographic: https://www.thelancet.com/infographics-do/universal-access-precision-oncology Read the full Commission: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00302-5
• 
  Tumour-infiltrating lymphocytes in breast cancer with Professor Sherene Loi 24.08.2026 17min

  Professor Sherene Loi and the International Immuno-Oncology Biomarker Working Group on tumour-infiltrating lymphocytes as breast cancer biomarkers. Two Articles cover AI and digital pathology scoring methods and a Review examines integrating TILs into radiation oncology trials and clinical practice. The Articles and Review are published in the September 2026 issue of The Lancet Oncology. To read the publications discussed, see:  Tumour-infiltrating lymphocytes and breast radiotherapy: perspectives from the International Immuno-Oncology Biomarker Working Group:  https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00255-X Artificial intelligence-based tumour infiltrating lymphocyte quantification in patients with triple-negative breast cancer: an independent validation study  https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00339-6   Manual, digital, and AI tumour-infiltrating lymphocyte scoring: a secondary analysis of the APHINITY randomised trial: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00247-0
• 
  5-year quality of life study of the SUPREMO trial examining chest wall radiotherapy in patients with intermediate-risk breast cancer with Professor Galina Velikova 27.07.2026 11min

  5-year quality of life (QOL) substudy of the SUPREMO trial examining the effects of chest wall radiotherapy versus no chest wall radiotherapy after mastectomy in patients with intermediate-risk breast cancer. The data will put patients in a better position to make an informed treatment decision considering long-term QOL effects for intermediate-risk early breast cancer. Click here to read the full article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00122-1/fulltext
• 
  Hans Merks on European guidelines for imaging of primary paediatric and adult osteosarcoma and Ewing sarcoma 29.06.2026 12min

  Imaging is central to osteosarcoma and Ewing sarcoma diagnosis and treatment, yet no international consensus defines optimal modalities or schedules to date. Hans presents harmonised European recommendations for the imaging of bone sarcomas, fulfilling the requirement for a methodical, systematic, and uniform approach to the diagnosis, treatment response assessment and post-therapy surveillance of osteosarcoma and Ewing sarcoma. Click here to read the full article:  https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00141-5/fulltext
• 
  Hedvig Hricak and Zachary Ward on Cancer workforce—a global crisis: a Lancet Oncology Commission 31.05.2026 23min

  Jamie Prowse, Senior Editor at The Lancet Oncology, is joined by Dr Hedvig Hricak (Memorial Sloan Kettering Cancer Center, New York, NY, USA) and Dr Zachary Ward (Harvard TH Chan School of Public Health, Boston, MA, USA) to discuss Cancer workforce—a global crisis: a Lancet Oncology Commission. To discover more about the commission click here: www.thelancet.com/commissions-do/cancer-workforce. To read the full commission click here: https://doi.org/10.1016/S1470-2045(26)00065-3
• 
  Fred Saad on quality of life in patients with metastatic hormone-sensitive prostate cancer 27.04.2026 13min

  Cheryl Lai, Acting Deputy Editor of The Lancet Oncology, is joined by Professor Fred Saad (Department of Surgery/Urology, University of Montreal, Montreal, QC, Canada) to discuss pain and health-related quality-of-life outcomes from the randomised phase 3 ARANOTE trial of darolutamide in metastatic hormone-sensitive prostate cancer. Hear about the findings from the study, the importance of quality of life for patients with metastatic prostate cancer, and how clinical research in metastatic hormone-sensitive prostate cancer might look in the next 5 years. Read the full article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00014-8/fulltext
• 
  James Nagarajah on [177Lu]-PSMA-617-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 study 31.03.2026 10min

  Cheryl Reeves, Senior Editor at The Lancet Oncology, is joined by Professor James Nagarajah to discuss his open-label, randomised, phase 2 study [177Lu]-PSMA-617-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE). Click here to read the full article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00762-4/fulltext Tell us what you thought about this episode Medical imaging and theranostics are revolutionising how we diagnose, treat, and understand dise...
• 
  Ali Landman on the European Congress of Radiology 2026 18.03.2026 15min

  Join us for this special episode where Deputy Editor Cheryl Lai speaks with Ali Landman, Editor-in-Chief of The Lancet Medical Imaging & Theranostics, about the scope and vision of the new journal and Ali's highlights in oncological imaging from the European Congress of Radiology in Vienna, March 4-8, 2026. To learn more: European Congress of Radiology: https://www.myesr.org/congress/ The Lancet Medical Imaging & Theranostics: https://www.thelancet.com/medical-imaging-theranostics ...
• 
  Kayleigh Bhangdia on breast cancer GBD study 2023 09.03.2026 18min

  Kayleigh Bhangdia discusses the latest GBD breast cancer study data, telling the audience about epidemiological trends, disease burden, and risk factors associated with breast cancer globally, regionally, and nationally for 204 countries from 1990 to 2023. Kayleigh sheds light on disparities in breast cancer burden across the globe and forecasts to 2050, and highlights the the most critical areas that future GBD studies should focus on to improve the accuracy, relevance, and impact of breast ...
• 
  Dylan Graetz and Erica Kaye on qualitative research in oncology 03.02.2026 42min

  Jamie Prowse, Senior Editor at The Lancet Oncology, is joined by Dr Dylan Graetz (Department of Oncology and Department of Global Pediatric Medicine, St Jude Children’s Research Hospital) and Dr Erica Kaye (Department of Oncology, St Jude Children’s Research Hospital) to discuss qualitative in oncology. Read the full Reviews: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00669-2 for The Power of Words: Evaluating the Role of Qualitative Methods in Cancer Research and h...
• 
  Jesse Plascak and Marissa Baker on cancer mortality rates by occupation among US workers 30.12.2025 23min

  Cheryl Lai, Senior Editor of The Lancet Oncology, is joined by Dr Jesse Plascak (Division of Cancer Prevention and Control, The Ohio State University) and Dr Marissa Baker (Department of Environmental & Occupational Health Science, University of Washington School of Public Health) to discuss their population-based study analysing cancer mortality rates by sex, cancer type, and occupation type among working-age adults in the USA. Read the full article: https://www.thelancet.com/journals/...
• 
  Andre Pfob and Peter Dubsky on The Lucerne Toolbox 3 25.11.2025 26min

  Dr Andre Pfob (Department of Obstetrics & Gynecology, Heidelberg University Hospital) and Prof Peter Dubsky (Faculty of Health Sciences and Medicine, University of Lucerne) discuss their Review entitled The Lucerne Toolbox 3: digital health and artificial intelligence to optimise the patient journey in early breast cancer—a multidisciplinary consensus. Click here to read the full article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00463-2/fulltext Tell us what you ...
• 
  Gary Rodin on The human crisis in cancer: a Lancet Oncology Commission 03.11.2025 10min

  Dr Gary Rodin discusses The human crisis in cancer: a Lancet Oncology Commission which identifies a growing imbalance between technological innovation and the human dimensions of cancer care. Click here to read the full Commission: The human crisis in cancer: a Lancet Oncology Commission And comment: Re-establishing human-centred care Tell us what you thought about this episode Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/t...
• 
  Matthias Preusser on the phase 2 TUXEDO-3 trial 28.10.2025 17min

  Deputy Editor Ali Landman speaks with Matthias Preusser (Medical University of Vienna, Vienna, Austria) about two reports from the phase 2 TUXEDO-3 trial investigating patritumab deruxtecan (HER3-Dxd) in patients with active brain metastases of breast cancer or non-small-cell lung cancer. Hear about the potential of HER3-targeted antibody-drug conjugates for brain metastases, why recruiting patients with active brain metastases to clinical trials is so important, and where the field is ...
• 
  Andrea Necchi on TAR-200 plus cetrelimab as neoadjuvant therapy in patients with muscle-invasive bladder cancer 30.09.2025 12min

  Smriti Patodia, Senior Editor of The Lancet Oncology, is joined by Dr Andrea Necchi, Associate Professor at the Vita-Salute San Raffaele University, and the Director of Genitourinary Medical Oncology at the San Raffaele Hospital, in Milan, Italy, to discuss his SunRISe4-trial published in our October issue. Effective treatments are needed for patients with muscle-invasive bladder cancer scheduled for radical cystectomy who are ineligible for or decline to receive neoadjuvant cisplatin-based ...
• 
  Linda Bi, Ruchit Patel, Chloe Gui, Farshad Nassiri, and Matija Snuderl on TERT expression and TERT promoter mutations in meningiomas 02.09.2025 14min

  Kat Gourd, Acting Deputy Editor of The Lancet Oncology, is joined by Dr Linda Bi, Dr Ruchit Patel, Dr Chloe Gui, Dr Farshad Nassiri, and Dr Matija Snuderl, from institutions in the USA and Canada, to discuss two exciting papers on TERT expression and TERT promoter mutations in meningiomas. In these two cohort studies, the authors analyse the expression of TERT and TERT promoter mutations in meningiomas, assess their association with patient outcomes, and discuss the potential implications fo...
• 
  Jinming Li on patterns in genomic mutations among patients with early-onset colorectal cancer 29.07.2025 7min

  Cheryl Reeves, Senior Editor at The Lancet Oncology, is joined by Dr Jinming Li, from the Department of Colorectal Surgery, Fudan University Shanghai Cancer Centre, Shanghai, China to discuss his international, multicohort, observational study on patterns in genomic mutations among patients with early-onset colorectal cancer. Read the full article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00239-6?dgcid=buzzsprout_icw_podcast_July_25_lanonc Tell us what you thought ab...
• 
  Abdalla Awidi on cancer control in the Middle East 12.06.2025 8min

  Jamie Prowse, Senior Editor at The Lancet Oncology, is joined by Professor Abdalla Awidi (Founder and Director of Stem Cell Therapy Center, University of Jordan, Amman, Jordan) to discuss The Lancet Oncology's Cancer control in the Middle East Series. The Series comprises five papers from regional experts who discuss the current outlook for cancer in the Middle East and future developments. See the whole Series here: https://www.thelancet.com/series-do/cancer-control-in-middle-east?dgcid=buzz...
• 
  ASCO 2025 Debrief 11.06.2025 14min

  Katherine Gourd, Acting Deputy Editor at The Lancet Oncology, and Vania Wisdom, Senior Executive Editor at The Lancet and the journal's Oncology Ambassador, join Leon Terner to share some of their experiences, impressions and highlights from this year's American Society of Clinical Oncology (ASCO) conference. If you haven't already, be sure to listen to Vania's pre-ASCO predictions podcast here: https://www.buzzsprout.com/882697/episodes/17233167 Articles discussed in this podcast episo...
• 
  Caroline Robert on treatments for patients with advanced melanoma with BRAFV600E or BRAFV600K mutations (EBIN trial) 29.05.2025 10min

  Smriti Patodia, Senior Editor of The Lancet Oncology, is joined by Professor Caroline Robert from Gustave Roussy Cancer Campus, France to discuss the EBIN trial. EBIN was an open-label, randomised, controlled, phase 2 trial conducted at 37 centres in eight European countries, and aimed to investigate the use of a targeted-therapy induction regimen before treatment with immune checkpoint inhibitors in patients with metastatic melanoma with BRAFV600E or BRAFV600K mutations. They discuss t...